Clinical Trials in China / NCT07070362
Recruiting
Observational
Digital Early Warning System for Acute Lung Injury in Liver Surgery
NCT07070362 · tracked via the Priya Life Science China tracker
Condition(s) studied
Acute Lung Injury(ALI)Liver CirrhosisARDS, HumanMASLDMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)NAFLD (Nonalcoholic Fatty Liver Disease)Liver Cancer, Adult
Study summary
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions. This model will enable early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will create a digital early-warning system for ALI, thereby supporting clinical diagnosis and treatment decisions. This, in turn, should help reduce the incidence and mortality rates associated with ALI.
Eligibility
Inclusion Criteria:
* Age ≥ 18 years
* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)
* Voluntary participation with signed informed consent
Primary outcome measure(s)
- Occurrence of ALI within 7 Days after Surgery — Perioperative period (Perioperative): Refers to the entire process from the determination of surgical treatment to postoperative rehabilitation (e.g., from 1 day before surgery to 7 days after surgery).
Berlin Definition: 1. Onset: Acute exacerbation of known injury or new/worsening respiratory symptoms within 1 week. 2. Chest Imaging (X-ray or CT): Bilateral pulmonary shadows not fully explained by exudation, atelectasis, or nodules. 3. Pulmonary Edema Etiology: Respiratory failure not fully attributed to heart failure or fluid overload; if no related risk factors, objective tests (e.g., Doppler echocardiography) are needed to exclude hydrostatic pulmonary edema. 4. Oxygenation Levels: Mild - With CPAP/PEEP \>5 cmH2O, 200 mmHg \< PaO2/FiO2 \< 300 mmHg; Moderate - With CPAP/PEEP \>5 cmH2O, 100 mmHg \< PaO2/FiO2 \< 200 mmHg; Severe - With CPAP/PEEP \>5 cmH2O, PaO2/FiO2 \< 100 mmHg.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine，Tsinghua University | Beijing | Beijing Municipality | Recruiting |
| Peking University International Hospital | Beijing | China | Recruiting |
| Southwest Hospital, The First Affiliated Hospital of Army Medical University | Chongqing | China | Recruiting |
| Huangdao District People's Hospital of Qingdao | Qingdao | China | Recruiting |
More Beijing Tsinghua Chang Gung Hospital trials in China
Other trials for the same condition
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Starting soon
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
Active, not recruiting
Establishment of a Model for Predicting the Prognosis of HBV-related Decompensated Liver Cirrhosis Based on RFH-NPT
Active, not recruiting
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
Enrolling by invitation
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07070362 on ClinicalTrials.gov ↗ ← All trials in China